‘Follow The Money’: Sweden’s Calliditas Plans US Listing
CEO Says NASDAQ Float Will Position Biotech Better Before Pivotal Readout
Executive Summary
Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.
You may also be interested in...
$90m IPO Sets Up Sweden's Calliditas For Phase III Readout
The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.
SwedenBio Snapshot Shows Vibrant Ecosystem
Sweden´s ecosystem for drug discovery and development is flourishing, seeded by academia, nurtured by incubators and funded from varied sources, 2020 report shows.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.